newly
granted
european
patent
protects
vbl
therapeutics
antibodies
inflammation
least
july
tel
aviv
israel
globe
newswire
vbl
therapeutics
nasdaq
vblt
today
announced
european
patent
office
epo
granted
patent
covers
vbl
proprietary
investigational
monoclonal
antibodies
treat
inflammatory
conditions
vbl
currently
advancing
lead
candidate
studies
vbl
recently
demonstrated
activity
antibodies
patients
progressive
multiple
sclerosis
ms
well
animal
models
rheumatoid
arthritis
ra
nonalcoholic
steatohepatitis
nash
inflammatory
bowel
disease
ibd
claims
granted
patent
cover
use
antibody
antibody
fragment
treat
wide
range
inflammatory
autoimmune
conditions
patent
expected
provide
protection
vbl
antibodies
inflammation
least
july
completely
novel
mechanism
targets
monocytes
believe
lead
drug
candidate
game
changer
many
chronic
inflammatory
diseases
said
dror
harats
chief
executive
officer
vbl
therapeutics
patent
provides
intellectual
property
protection
platform
technology
important
business
advantage
advance
program
enter
clinic
company
recently
held
meeting
fda
reached
alignment
agency
path
forward
lead
candidate
study
planned
commence
second
half
vbl
platform
vbl
conducting
two
parallel
drug
development
programs
exploring
potential
motile
sperm
protein
protein
vbl
identified
key
regulator
cell
motility
therapeutic
target
inflammatory
diseases
cancer
company
platform
comprises
classical
monoclonal
antibodies
inflammatory
indications
well
antibody
candidates
oncology
vbl
vascular
biogenics
operating
vbl
therapeutics
clinical
stage
biopharmaceutical
company
focused
discovery
development
commercialization
treatments
areas
unmet
need
cancer
immune
inflammatory
indications
vbl
developed
three
platform
technologies
based
technology
targeting
newly
formed
blood
vessels
focus
cancer
technology
targeting
applications
lecinoxoids
family
indications
vbl
lead
oncology
product
candidate
ofranergene
obadenovec
targeted
agent
developed
treat
wide
range
solid
tumors
conveniently
administered
iv
infusion
every
weeks
observed
cancer
patients
demonstrated
activity
signals
comers
phase
trial
well
three
phase
studies
ofranergene
obadenovec
currently
studied
phase
potential
registration
trial
ovarian
cancer
forward
looking
statements
press
release
contains
statements
statements
statements
historical
fact
statements
often
indicated
terms
anticipate
believe
could
estimate
expect
goal
intend
look
forward
may
plan
potential
predict
project
would
similar
expressions
statements
include
limited
statements
regarding
programs
including
including
clinical
development
timing
clinical
trials
expected
announcement
data
therapeutic
potential
clinical
results
financial
position
cash
runway
statements
promises
guarantees
involve
substantial
risks
uncertainties
among
factors
could
cause
actual
results
differ
materially
described
projected
herein
include
uncertainties
associated
generally
research
development
clinical
trials
related
regulatory
reviews
approvals
risk
historical
clinical
trial
results
may
predictive
future
trial
results
impact
pandemic
business
operations
clinical
trials
supply
chain
strategy
goals
anticipated
timelines
clinical
results
financial
resources
last
long
anticipated
may
realize
expected
benefits
intellectual
property
protection
list
description
risks
uncertainties
risks
found
regulatory
filings
securities
exchange
commission
including
annual
report
form
year
ended
december
subsequent
filings
sec
existing
prospective
investors
cautioned
place
undue
reliance
statements
speak
date
hereof
vbl
therapeutics
undertakes
obligation
update
revise
information
contained
press
release
whether
result
new
information
future
events
circumstances
otherwise
investor
contact
michael
rice
lifesci
advisors
mrice
